Friday 6 November 2026
Export RGEN’s income statement to Excel — free account
Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- −351.9%
- Free cash flow
- −11.5%
- Total debt
- +3.28%
Quarter to September 2026, against a year earlier
173.01
4.53
+2.69%
Follow RGEN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 7 | 7 | 5 |
| 2.40% | 2.51% | 1.99% | (0.57%) | ||
| 1.69% | 1.78% | 1.42% | (0.40%) | ||
ROIC |
1.83% | 2.16% | 2.18% | 0.64% | |
Return on Tangible Assets |
4.12% | 4.25% | 3.36% | (0.92%) | |
Average Days of Receivables |
78.41 | 72.47 | 73.32 | 68.52 | |
Free Cash Flow per Share |
1.63 | 1.86 | 1.96 | 1.86 | |
Free Cash Flow |
91.93 | 104.66 | 110.35 | 105.45 | |
Capital Expenditures |
(25.49) | (26.05) | (24.51) | (24.41) | |
| Other line items | |||||
Cash ROIC |
2.69% | 3.05% | 3.18% | 3.00% | |
Accounts Receivable Turnover |
5.04 | 5.11 | 4.99 | 5.37 | |
Accounts Payable Turnover |
11.33 | 11.70 | 12.40 | 13.13 | |
Inventory Turnover |
2.25 | 2.17 | 2.13 | 2.19 | |
Average Days of Payables |
31.12 | 35.12 | 33.24 | 26.96 | |
Days of Inventory on Hand |
176.75 | 181.65 | 186.65 | 177.38 | |
Tax Rate |
(0.22) | (0.09) | (0.20) | (2.43) | |
Research and Development Expense of Revenue |
7.34% | 7.40% | 7.26% | 7.10% | |
Selling, General and Administrative Expense of Revenue |
39.35% | 38.82% | 38.47% | 38.73% | |
Share Based Compensation of Revenue |
4.42% | 4.41% | 4.24% | 4.18% | |
Interest Coverage |
2.56 | 2.95 | 2.92 | 0.81 | |
Operating CF/Net income |
2.40 | 2.54 | 3.25 | (11.00) | |
Depreciation/Fixed assets |
0.51 | 0.56 | 0.58 | 0.84 | |
Capex/Depreciation |
(0.27) | (0.27) | (0.25) | (0.18) | |
Revenue per Share |
13.13 | 13.55 | 13.92 | 14.24 | |
Operating CF per Share |
2.09 | 2.32 | 2.39 | 2.30 | |
Capex per Share |
(0.45) | (0.46) | (0.43) | (0.43) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026